당뇨병성 위마비 치료제 시장 : 제품 유형별, 적응증별, 유통 채널별, 지역별 시장 규모, 점유율, 전망, 기회 분석(2023-2030년)
Diabetic Gastroparesis Treatment Market, By Product Type (Drugs, Surgical Treatment Products ), By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
상품코드
:
1304161
리서치사
:
Coherent Market Insights
발행일
:
2023년 05월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
위마비는 기계적 막힘 없이 위 배출이 지연되는 증상입니다. 당뇨병 성 위마비는 자율 신경계, 신경 세포, 위 및 장의 특수 심장 박동기 세포, 소화관의 평활근 세포의 조정 및 기능 장애로 인해 통제되지 않은 당뇨병 환경에서 발생할 수있는 잠재적인 합병증입니다. 당뇨병성 위마비는 자율신경계와 장신경계의 기능 장애의 결과로 발생합니다. 만성 고혈당(또는 비효율적 인 포도당 섭취)은 신경 세포 손상을 유발하여 장 신경 전달의 이상, 억제성 신경 세포 기능 저하, 위 평활근 및 심장 박동기 세포의 기능 장애를 초래합니다.
이 기능 장애로 인해 항문 수축이 감소하고 항문 및 십이지장 수축이 조율되지 않아 유문 경련이 발생하여 결국 위 배출 지연(위마비)이 발생합니다. 당뇨병 환자의 위 배출 지연, 특히 고형물 배출 지연은 소장의 운동 이상에서도 발생할 수 있으며, 이는 위에서 설명한 것과 유사한 메커니즘으로 발생하는 것으로 예상됩니다. 일부 당뇨병 환자는 위 순응도가 증가하거나 감소하는 변화를 경험할 수 있으며, 이 또한 위 배출 지연의 원인이 될 수 있습니다.
시장 역학
세계 당뇨병 유병률 증가, 노인 인구 증가와 좌식 생활습관 증가, 환자들의 약물치료에 대한 경제성 및 접근성 향상, 당뇨병성 위마비 관련 연구 및 개발 활동이 세계 당뇨병성 위마비 치료제 시장 성장에 기여하고 있습니다. 예를 들어, 2020년 6월 23일 미국 식품의약국(FDA)은 미국 제약회사 에보크 파마(Evoke Pharma)가 급성 및 재발성 당뇨병성 위마비 성인의 증상을 완화하는 기모티(Gimoti) 비강 스프레이에 대한 신약 신청을 승인했다고 발표했습니다. 메토클로프라미드(Metoclopramide)라는 약물은 부작용이 있어 사용이 제한되어 있습니다. 그래서 비강으로 약물을 도입하는 새로운 접근법을 택했습니다.
조사의 주요 특징
- 이 보고서는 세계의 당뇨병성 위마비 치료 시장을 상세하게 분석하고, 2022년을 기준연도로 하여 예측 기간(2023-2030년) 시장 규모와 복합 연간 성장률(CAGR)을 제공합니다.
- 또한 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에 대한 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략 등에 대한 중요한 고려 사항도 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등 다양한 매개 변수를 기반으로 세계 당뇨병성 위부전증 시장의 주요 기업들을 프로파일링합니다.
Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc.（Becton, Dickinson and Company）, Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc가 있습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대 및 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 당뇨병성 위마비 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계 당뇨병성 위마비 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 상황 개요
- 보고서 개요
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 시장 기회
- 영향 분석
- 최근의 제품 출시
- 역학
- 인수합병(M&A) 및 협업
- 규제 시나리오
- 주요 발전
- PEST 분석
제4장 세계의 당뇨병성 위마비 치료 시장 : 코로나바이러스(COVID-19) 팬데믹의 영향
- 경제적 영향
- COVID-19 역학
- 수급에 대한 영향
제5장 세계의 당뇨병성 위마비 치료 시장 : 제품 유형별, 2018년-2030년
- 약제
- 소화관 운동 기능 개선제
- 제제
- 보툴리눔톡신(보톡스)
- 외과 치료 제품
- 위전기 자극(GES) 기기
- 경피 내시경적 위루 조설술(PEG) 키트
- 비경구 영양제
제6장 세계의 당뇨병성 위마비 치료 시장 : 질환 적응별, 2018년-2030년
제7장 세계의 당뇨병성 위마비 치료제 시장 : 유통 채널별, 2018년-2030년
제8장 세계의 당뇨병성 위마비 치료제 시장 : 지역별, 2018년-2030년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
- 기타 라틴아메리카
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 중동
- GCC
- 이스라엘
- 기타 중동
- 아프리카
- 북아프리카
- 중앙아프리카
- 남아프리카
제9장 경쟁 구도
- Janssen Global Services, LLC
- Cardinal Health, Inc.
- Evoke Pharma, Inc.
- Salix Pharmaceuticals, Inc.
- Alfa Wassermann SPA
- Abbott Laboratories
- Medtronic Plc
- C.R. Bard, Inc.(Becton, Dickinson and Company)
- Rhythm Pharmaceuticals, Inc.
- Boston Scientific Corporation
- Kimberly-Clark Corporation.
- Vanda Pharmaceuticals, Inc.
- Allergan, plc.
제10장 섹션
LSH
영문 목차
Gastroparesis is the delaying of gastric emptying without any evidence of mechanical obstruction. Diabetic gastroparesis is a potential complication that occurs in the setting of poorly controlled diabetes, resulting from dysfunction in the coordination and function of the autonomic nervous system, neurons, and specialized pacemaker cells of the stomach and intestine, and the smooth muscle cells of the gastrointestinal tract. Diabetic gastroparesis occurs as a result of dysfunction in the autonomic and enteric nervous systems. Chronically high levels of blood glucose (or inefficient glucose uptake) lead to neuronal damage resulting in abnormal myenteric neurotransmission, impaired inhibitory neuronal function, and dysfunctional smooth muscle and pacemaker cells of stomach.
Altogether, this dysfunction results in a combination of fewer contractions of the antrum, uncoordinated antro-duodenal contractions, and pyloric spasms, ultimately resulting in delayed gastric emptying (gastroparesis). Delayed gastric emptying in patients with diabetes, particularly of solids, may also occur in the setting of abnormal small bowel motility, which is thought to occur by a similar mechanism as that which is described in the stomach. Some patients with diabetes may additionally experience changes in gastric compliance, both increased or decreased, which may also contribute to delayed gastric emptying.
Market Dynamics
Increasing prevalence of diabetes worldwide, increasing geriatric population and sedentary lifestyle, increasing affordability and accessibility of medication to patients, and research and development activities on diabetic gastroparesis attributed to the growth of global diabetic gastroparesis treatment market. For instance, on June 23, 2020, Evoke Pharma, a U.S.-based pharmaceutical company, announced that the U.S. Food And Drug Administration has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The drug, Metoclopramide has limited use due to associated side effects. Hence, a novel approach by introducing drug in trans nasal pathway is taken.
Key features of the study:
- This report provides an in-depth analysis of the Global Diabetic Gastroparesis Treatment Market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetic gastroparesis market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic gastroparesis treatment market
Detailed Segmentation:
- Global Diabetic Gastroparesis Treatment Market, By Product Type:
- Drugs
- Gastroprokinetic Agents
- Antiemetic Agents
- Botulinum Toxin
- Surgical Treatment Products
- Gastric Electrical Stimulation (GES) Device
- Percutaneous Endoscopic Gastrostomy (PEG) Kit
- Parenteral Nutrition
- Global Diabetic Gastroparesis Treatment Market, By Disease Indication:
- Compensated Gastroparesis
- Gastric Failure
- Global Diabetic Gastroparesis Treatment Market, By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Diabetic Gastroparesis Treatment Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Janssen Global Services *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- LLC, Cardinal Health, Inc.
- Evoke Pharma, Inc.
- Salix Pharmaceuticals, Inc.
- Alfa Wassermann SPA
- Abbott Laboratories
- Medtronic Plc.,
- C.R. Bard, Inc. (Becton, Dickinson and Company)
- Rhythm Pharmaceuticals, Inc.
- Boston Scientific Corporation
- Kimberly-Clark Corporation
- Vanda Pharmaceuticals, Inc.
- Allergan, plc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Diabetic Gastroparesis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2018 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Gastroprokinetic Agents
- Antiemetic Agents
- Botulinum Toxin
- Surgical Treatment Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment trends
- Gastric Electrical Stimulation (GES) Device
- Percutaneous Endoscopic Gastrostomy (PEG) Kit
- Parenteral Nutrition
6. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2018 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Compensated Gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Gastric Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
7. Global Diabetic Gastroparesis Treatment Market, By Distribution channel, 2018 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
8. Global Diabetic Gastroparesis Treatment Market, By Region, 2018 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel , 2018 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018- 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Janssen Global Services, LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cardinal Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Evoke Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Salix Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alfa Wassermann SPA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Medtronic Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- C.R. Bard, Inc. (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Rhythm Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boston Scientific Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kimberly-Clark Corporation.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Vanda Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Allergan, plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
관련자료
